661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. (23rd October 2018) - Bang, Y-J; Doi, T; Kondo, S; Chung, H C; Muro, K; Dussault, I; Helwig, C; Osada, M; Kang, Y-K